AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday. They presently have a $7.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $12.00. HC Wainwright’s target price suggests a potential upside of 183.02% from the company’s current price.
Several other equities research analysts also recently weighed in on AEZS. Zacks Investment Research downgraded AEterna Zentaris from a “buy” rating to a “hold” rating in a research report on Tuesday, October 11th. Maxim Group reaffirmed a “buy” rating and set a $10.00 price target (down from $11.00) on shares of AEterna Zentaris in a research report on Thursday, November 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $7.50 price target (down from $9.00) on shares of AEterna Zentaris in a research report on Friday, November 11th.
Shares of AEterna Zentaris (NASDAQ:AEZS) traded down 3.64% during trading on Tuesday, hitting $2.65. The stock had a trading volume of 255,362 shares. The firm’s market cap is $30.93 million. AEterna Zentaris has a 12-month low of $2.35 and a 12-month high of $5.59. The firm has a 50 day moving average price of $3.60 and a 200 day moving average price of $3.59.
TRADEMARK VIOLATION NOTICE: “AEterna Zentaris Inc. (AEZS) Rating Reiterated by HC Wainwright” was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was illegally copied and reposted in violation of United States & international copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/aeterna-zentaris-inc-aezs-rating-reiterated-by-hc-wainwright/342576.html.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with our FREE daily email newsletter.